Finance

Beta
Lists
AUTL:NASDAQ
Autolus Therapeutics PLC
$1.61
+1.26%
(+0.020) 1D
$1.61
0.00% (0.00)
After hours
Closed: Jun 26, 4:00:02 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AUTL...
Open
$1.59
High
$1.66
Low
$1.58
Mkt. cap
428.51M
Avg. vol.
1.50M
Volume
744.84K
52-wk high
$2.70
52-wk low
$1.18
EPS
-$1.09
Beta
2.02
Shares outstanding
266.16M
No. of employees
753
Open
$1.59
High
$1.66
Low
$1.58
Mkt. cap
428.51M
Avg. vol.
1.50M
Volume
744.84K
52-wk high
$2.70
52-wk low
$1.18
EPS
-$1.09
Beta
2.02
Shares outstanding
266.16M
No. of employees
753
News stories
From sources across the web
About Autolus Therapeutics PLC
CEOChristian Itin
Employees753
Founded2014
Headquarters-
SectorBiotechnology
Websiteautolus.com
Analyst ratings
Based on 6 analysts giving stock ratings to AUTL in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AUTL in the last 3 months.
Highest
Current $1.61
$10.00 (+521.12%)
Average
$8.08 (+401.86%)
Lowest
$5.00 (+210.56%)
Analyst
Recommendation
Action
Price target
Projected
Date
Salim Syed
Mizuho Securities
Buy
Maintained
$10.00
+521.1%
06/10/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
06/02/2026
Unknown Analyst
Wells Fargo
Buy
Reiterated
$5.00
+210.6%
05/15/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
$5.40
+235.4%
05/15/2026
Gil Blum
Needham
Buy
Maintained
$10.00
+521.1%
05/14/2026
Emily Bodnar
H.C. Wainwright
Buy
Reiterated
$10.00
+521.1%
05/13/2026
Last report
May 14, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.27 / -$0.26
-4.20%miss
Revenue / Est. (USD)
26.22M / 26.13M
+0.33%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
20.92M
21.19M
24.29M
26.22M
Cost of goods sold
25.97M
56.54M
54.29M
45.78M
Cost of revenue
25.97M
56.54M
54.29M
45.78M
Research and development expenses
25.90M
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
30.26M
36.28M
42.12M
39.95M
Operating expense
56.17M
36.28M
42.12M
39.95M
Total operating expenses
82.14M
92.82M
96.41M
85.73M
Operating income
-61.22M
-71.62M
-72.12M
-59.51M
Other non operating income
17.66M
84.00K
-11.66M
100.00K
EBT including unusual items
-47.52M
-78.59M
-91.52M
-70.74M
EBT excluding unusual items
-47.52M
-78.59M
-91.17M
-70.74M
Income tax expense
397.00K
532.00K
-1.18M
863.00K
Effective tax rate
-0.84%
-0.68%
1.29%
-1.22%
Other operating expenses
-
-
-
-
Net income
-47.92M
-79.12M
-90.33M
-71.60M
Net profit margin
-229.02%
-373.30%
-371.90%
-273.09%
Earnings per share
-0.18
-0.30
-0.34
-0.27
Interest and investment income
5.23M
4.38M
3.23M
2.47M
Interest expense
-10.70M
-10.52M
-11.01M
-11.12M
Net interest expenses
-5.46M
-6.14M
-7.78M
-8.66M
Depreciation and amortization charges
-
-
-
-
EBITDA
-58.85M
-69.08M
-69.49M
-56.81M
Gain or loss from assets sale
-
-
11.00K
2.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of AUTL
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer